Abstract: In the past decade, the emergence of targeted therapy has provided an exciting option for the treatment of renal cell carcinoma. There were 9 targeting agents approved for the treatment of unresectable or metastatic renal carcinoma by the American Food and Drug Administration(FDA). The promise of renal carcinoma immunotherapy was officially validated in December 2015 when the FDA approved Nivoliumab for the treatment of metastatic renal carcinoma. There are an increasing number of clinical trials on immune checkpoint inhibitors alone or combined with targeting agents that are now being identified and used for renal carcinoma immunotherapy. In this review, we present a brief overview of current treatments and discuss major clinical trials and data on renal carcinoma.